Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 518 across all filing types
Latest filing 2017-11-06 Regulatory Filings
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Zakończenie etapu prac nad projektem PCR|ONE - Content (PL)
Regulatory Filings Classification · 92% confidence The document is a formal announcement from the Management Board ('Zarząd') of Scope Fluidics S.A. regarding the completion of a specific research and development stage ('pierwszego etapu prac badawczo-rozwojowych') for their PCR|ONE system. It details technical achievements (optimization of the chip, DNA isolation, amplification, and detection) and confirms that a key milestone has been met according to a previously disclosed schedule. This type of announcement, detailing progress on a specific project or technical development, does not fit neatly into standard financial reporting categories (10-K, IR, ER). It is a specific operational/project update. Since it is not a standard regulatory filing, a management change, or a financing event, it best fits the general 'Regulatory Filings' category as a miscellaneous, specific corporate announcement that doesn't have its own dedicated code, or potentially 'Capital/Financing Update' if the R&D was tied to specific funding milestones, but the text focuses purely on technical progress. Given the options, 'RNS' (Regulatory Filings/Miscellaneous Announcement) is the most appropriate fallback for a detailed operational update that isn't a standard financial report or governance document.
2017-11-06 Polish
zawiadomienie o transakcji _Szymon Ruta
Director's Dealing Classification · 99% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction/transactions referred to in Article 19(1) of the MAR Regulation). Article 19 of the Market Abuse Regulation (MAR) specifically mandates reporting of transactions conducted by persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. The content details transactions (acquisition of subscription warrants and shares) by a board member ('Członek Zarządu') of Scope Fluidics S.A. This directly corresponds to the definition of Director's Dealing (insider trades). Comparing this to the provided definitions: - 10-K, AR, IR: These are comprehensive financial reports, which this is not. - ER, MRQ: These relate to earnings or major shareholding changes, not individual director trades. - DEF 14A: Relates to remuneration. - The closest match is 'Director's Dealing' (Code: DIRS), which covers reports of personal share transactions by company directors and executives.
2017-10-18 Polish
Otrzymanie zawiadomienia od osoby pełniącej obowiązki zarządcze - Content (PL)
Director's Dealing Classification · 95% confidence The document text is very short (385 characters) and explicitly states that a notification ('zawiadomienie') regarding a transaction by a person discharging managerial responsibilities (PDMR) under MAR Regulation Article 19 has been received and that the 'full content of the notification is attached to this report' ('Pełną treści zawiadomienia załączono do niniejszego raportu.'). This structure—a brief announcement stating an official document is attached—strongly suggests a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS), rather than the detailed transaction report itself. Since the content describes the publication of a specific regulatory notice (insider dealing under MAR), and the 'Director's Dealing' (DIRS) definition covers reports of personal share transactions by directors, this is the most specific fit, even though the document itself is just the announcement wrapper. Given the context of MAR Article 19, DIRS is the most appropriate specific category for the underlying subject matter, but the 'MENU VS MEAL' rule suggests RPA/RNS because the actual data is attached. However, DIRS is specifically for 'Report of personal share transactions by company directors and executives (insider trades)'. Since the text is an announcement *about* such a report, and it's not a generic RNS, I will classify it as DIRS, assuming the attached document contains the required DIRS information, as this is a common pattern for MAR 19 filings being classified by subject matter. If the system strictly enforces the 'announcement wrapper' rule, RPA would be chosen. Given the high specificity of DIRS for MAR 19 filings, I lean towards DIRS as the subject classification, but acknowledge the wrapper nature. Re-evaluating: The text is a notification *of receiving* a MAR 19 notification. This is fundamentally an insider transaction report announcement. DIRS is the best fit for the subject matter. Confidence is high due to the clear reference to MAR Article 19.
2017-10-18 Polish
Status projektu Bacteromic - zakończeniu pierwszego etapu - Content (PL)
Regulatory Filings Classification · 95% confidence The document text is very short (846 characters) and appears to be an official announcement from the Management Board ("Zarząd Scope Fluidics S.A.") regarding the completion of a specific stage of research and development (R&D) work on the Bacteromic system. It details the completion of a project phase, the creation of prototypes, and the identification of potential patentable solutions. This type of announcement, detailing operational progress, R&D milestones, or specific project updates that are not standard financial reports (10-K, IR) or earnings releases (ER), often falls under general regulatory announcements or specific operational updates. Since there is no specific category for R&D milestone completion, and it is not a standard financial report, a dividend notice, or a management change, it fits best as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the R&D was tied to specific funding, but RNS is the most appropriate fallback for non-standard operational news releases. Given the content is a specific operational update about R&D progress and intellectual property planning, and it is not a standard financial report, RNS (Regulatory Filings) is the most suitable classification as a general regulatory announcement.
2017-10-02 Polish
Zawarcie znaczącej umowy – podpisanie umowy najmu lokalu - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a short announcement (1343 characters) from the Management Board ('Zarząd') of Scope Fluidics S.A. written in Polish. It details the signing of a 36-month lease agreement for new office/lab space, explaining the necessity due to company growth and the expiration of the current lease. This concerns a significant operational change related to facilities and expansion, but it does not fit neatly into standard financial reporting categories like 10-K, ER, or IR. It is not a Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP). Since it is an announcement about a significant operational/business development that doesn't map to a more specific category (like M&A or Financing), it falls best under the general 'Regulatory Filings' category as a miscellaneous corporate announcement, or potentially 'LTR' if viewed as a material contract update, but 'RNS' is the designated fallback for non-standard regulatory announcements. Given the content is a material business update (new lease, relocation due to growth), and it is not a standard financial report, RNS (Regulatory Filings) is the most appropriate general classification.
2017-09-28 Polish
Lista akcjonariuszy posiadających ponad 5% głosów na Nadzwyczajnym Walnym Zgromadzeniu Spółki w dniu 20.09.2017 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document text is very short (469 characters) and explicitly details the voting results from a specific shareholder meeting, the 'Nadzwyczajnym Walnym Zgromadzeniu' (Extraordinary General Meeting or EGM). It lists the shareholders who held over 5% of the votes and the percentage of votes they cast at that meeting. This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2017-09-20 Polish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.